PDCD1 and non-small cell lung carcinoma: Subsequently, an anti-PD-1 antibody, pembrolizumab (KEYNOTE-010 trial) [4], and an anti-programmed death-ligand 1 (PD-L1) antibody, atezolizumab (OAK trial) [5], were introduced as second-line treatments for NSCLC.